Latest News on JBIO

Financial News Based On Company


Advertisement
Advertisement

JBIO: Q12-week APRIL blockade anchors a three-program pipeline and an accelerated Phase III push

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4638652:0-jbio-q12-week-april-blockade-anchors-a-three-program-pipeline-and-an-accelerated-phase-iii-push/
Jade Biosciences, Inc. (JBIO) is advancing its JADE101 program towards Phase III initiation this quarter, with Phase II data anticipated in Q2 2027 and a Q12-week dosing goal. The company's pipeline also includes JADE201 and JADE301, both targeting data milestones in 2027. This information is based on an audio transcript from the UBS Global Biopharma Conference 2026.

Form 8K Jade Biosciences Inc For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-jade-biosciences-inc-for-13-november-93CH-4956476
This article announces that Jade Biosciences Inc. has filed a Form 8K on November 13. The company's stock symbol is JBIO, which saw a -4.05% change. The content primarily serves as a placeholder for the SEC filing, directing readers to view all comments regarding this news.

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.manilatimes.net/2026/11/13/tmt-newswire/globenewswire/jade-biosciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update/2469502
Jade Biosciences announced its Q3 2026 financial results, reporting $475.7 million in cash and investments, expected to fund operations into Q4 2028. The company is advancing its clinical pipeline, with the JADE101 Phase 3 trial in IgA nephropathy expected to start in Q4 2026 and interim data from other trials anticipated in 2027. Brad Dahms' role was expanded to Chief Financial Officer and Chief Business Officer to lead business development and corporate strategy.

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.globenewswire.com/news-release/2026/11/13/3402493/0/en/jade-biosciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html
Jade Biosciences announced its Q3 2026 financial results, reporting $475.7 million in cash, cash equivalents, and investments expected to fund operations into Q4 2028. The company also provided a corporate update on its pipeline, including the planned initiation of the JADE101 Phase 3 trial ahead of schedule and the advancement of JADE301 into Phase 1 clinical trials, demonstrating significant progress in its autoimmune disease therapies.

Jade Biosciences to Participate in Upcoming Conferences

https://www.globenewswire.com/news-release/2026/11/03/3394064/0/en/jade-biosciences-to-participate-in-upcoming-conferences.html
Jade Biosciences, a clinical-stage biotechnology company, announced its participation in four upcoming healthcare innovation and biopharma conferences in November 2026. Management will host one-on-one investor meetings, and live webcasts of the fireside chats will be available on their website. The company is focused on developing therapies for autoimmune diseases, with lead candidate JADE101 currently being evaluated for immunoglobulin A nephropathy.
Advertisement

BTIG Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $77

https://www.moomoo.com/news/post/1002413848/btig-maintains-jade-biosciences-jbious-with-buy-rating-maintains-target
BTIG has reiterated its Buy rating for Jade Biosciences (JBIO.US) and maintained its target price at $77. This indicates continued confidence in the company's performance and future outlook from the investment firm.

BTIG reiterates Buy rating on Jade Biosciences, $77 price target

https://www.tradingview.com/news/tradingview:46f215e19f7e1:0-btig-reiterates-buy-rating-on-jade-biosciences-77-price-target/
BTIG has reiterated a Buy rating on Jade Biosciences (JBIO) with a $77 price target, implying a 431.0% upside. The positive outlook is driven by the strong competitive positioning of JADE101, which showed a significant reduction in IgA levels in Phase 1 trials for immunoglobulin A nephropathy, and a promising pipeline including JADE201 and JADE301 with upcoming data releases. Other analysts from Wedbush and HC Wainwright & Co. also have Outperform or Buy ratings for JBIO.

Jade Biosciences, Inc. Estimates – NASDAQ:JBIO

https://www.tradingview.com/symbols/NASDAQ-JBIO/financials-estimates/
This article provides an overview of Jade Biosciences, Inc. (NASDAQ: JBIO) financials and estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing for comparison of actual results with average, high, and low estimates. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

https://au.finance.yahoo.com/news/jade-biosciences-highlight-advancement-jade101-110000845.html
Jade Biosciences announced that it will present three posters related to its JADE101 development program for IgA nephropathy (IgAN) at ASN Kidney Week 2026. The presentations will cover the scientific foundation and clinical advancement of JADE101, including the accelerated initiation of the EVERGREEN Phase 3 clinical trial expected in Q4 2026, and interim data from the JUNIPER Phase 2 trial anticipated in Q2 2027. This acceleration reflects the company's confidence in JADE101's potential as a best-in-class therapy.

Jade Biosciences to Highlight Advancement of JADE101

https://www.globenewswire.com/news-release/2026/10/21/3385377/0/en/jade-biosciences-to-highlight-advancement-of-jade101-development-program-at-american-society-of-nephrology-asn-kidney-week-2026.html
Jade Biosciences will present three posters related to its JADE101 program for IgA nephropathy at ASN Kidney Week 2026, including plans to accelerate the EVERGREEN Phase 3 clinical trial, now expected to start in Q4 2026. Interim data from the JUNIPER Phase 2 trial are anticipated in Q2 2027. These presentations underscore the scientific foundation and clinical progress of JADE101, which is positioned as a potential best-in-class therapy for the autoimmune kidney disease.
Advertisement

About 169,000 Americans have IgA kidney disease. Jade expects its trial to start this quarter.

https://www.stocktitan.net/news/JBIO/jade-biosciences-to-highlight-advancement-of-jade101-development-6zhuk46l22iv.html
Jade Biosciences (NASDAQ: JBIO) announced it anticipates initiating its EVERGREEN Phase 3 trial for JADE101, an investigational treatment for IgA nephropathy, in the fourth quarter of 2026, which is ahead of schedule. The company also expects interim data from the ongoing JUNIPER Phase 2 trial in the second quarter of 2027. These updates will be highlighted at the American Society of Nephrology (ASN) Kidney Week 2026.

Jade Biosciences presents JADE101 trial updates at ASN Kidney Week 2026

https://www.streetinsider.com/Corporate+News/Jade+Biosciences+presents+JADE101+trial+updates+at+ASN+Kidney+Week+2026/27212906.html
Jade Biosciences announced three poster presentations for its investigational drug JADE101 at the American Society of Nephrology Kidney Week 2026. JADE101 is being developed for immunoglobulin A nephropathy (IgAN). The company expects to initiate the Phase 3 EVERGREEN trial ahead of schedule in Q4 2026 and anticipates interim data from the Phase 2 JUNIPER trial in Q2 2027.

Jade Biosciences to Highlight Advancement of JADE101

https://www.globenewswire.com/de/news-release/2026/10/21/3385377/0/en/jade-biosciences-to-highlight-advancement-of-jade101-development-program-at-american-society-of-nephrology-asn-kidney-week-2026.html
Jade Biosciences will present three posters on its JADE101 development program for IgA nephropathy at ASN Kidney Week 2026, highlighting the scientific foundation and clinical advancement. The company anticipates initiating the EVERGREEN Phase 3 trial earlier than expected, in Q4 2026, and expects interim data from the JUNIPER Phase 2 trial in Q2 2027. These presentations underscore the potential of JADE101 as a best-in-class therapy for this chronic autoimmune kidney disease.

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

https://ca.finance.yahoo.com/news/jade-biosciences-highlight-advancement-jade101-110000845.html
Jade Biosciences announced that three posters related to its JADE101 development program for immunoglobulin A nephropathy (IgAN) will be presented at ASN Kidney Week 2026. The company is accelerating the EVERGREEN Phase 3 clinical trial for JADE101, now expected to initiate in the fourth quarter of 2026, and anticipates interim data from the JUNIPER Phase 2 trial in the second quarter of 2027. These presentations highlight the scientific foundation and clinical advancement of JADE101, aiming for a best-in-class profile with potent IgA reductions.

how InvestingPro’s fair value flagged Jade Biosciences’ 48% decline By Investing.com

https://ca.investing.com/news/stock-market-news/how-investingpros-fair-value-flagged-jade-biosciences-48-decline-93CH-4867437
InvestingPro's Fair Value analysis accurately predicted a 47.6% decline in Jade Biosciences (NASDAQ:JBIO) shares. In April 2026, when the stock was trading at $26.85, the analysis identified it as significantly overvalued with an intrinsic value of $15.62. By September 30, 2026, the stock had fallen to $14.07, validating the overvaluation signal and demonstrating the tool's ability to help investors avoid losses.
Advertisement

Jade Biosciences Inc (JBIO-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/JBIO/
This article provides stock information and news updates for Jade Biosciences Inc. (JBIO-Q), a company focused on developing therapies for autoimmune diseases. It lists recent analyst insights and company announcements, including progress towards clinical trials and board appointments. The company's pipeline includes antibody discovery programs JADE-002 and JADE-003, currently in preclinical development.

Jade Biosciences Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

https://www.moomoo.com/news/post/1000503339/jade-biosciences-price-target-maintained-with-a-55-00-share
HC Wainwright & Co. has reiterated its Buy rating for Jade Biosciences (OTCQB:JADE) and maintained a price target of $55.00 per share. This indicates continued confidence from the firm in the company's future performance.

Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4913734/analysts-are-bullish-on-top-healthcare-stocks-jade-biosciences-jbio-liquidia-technologies-lqda/
Two healthcare stocks, Jade Biosciences (JBIO) and Liquidia Technologies (LQDA), have received bullish ratings from analysts. Jade Biosciences was reiterated with a Buy rating and has a "Strong Buy" consensus with significant upside potential. Liquidia Technologies also maintained a Buy rating and holds a "Moderate Buy" consensus.

Stifel reiterates Jade Biosciences stock rating on drug data

https://www.investing.com/news/analyst-ratings/stifel-reiterates-jade-biosciences-stock-rating-on-drug-data-93CH-4925652
Stifel reiterated a Buy rating and a $40.00 price target for Jade Biosciences (NASDAQ:JBIO) following new preclinical data for its drug candidate JADE301. JADE301, an anti-IFN-β monoclonal antibody, is being developed for Dermatomyositis and shows improved affinity, potency, and half-life compared to existing treatments. Jade Biosciences plans to start a Phase 1 trial in Q4 2026, with interim results expected in H2 2027, aiming to achieve better dosing and potentially expand indications to other IFN-β driven diseases.

Stifel reiterates Jade Biosciences stock rating on drug data By Investing.com

https://ng.investing.com/news/stock-market-news/stifel-reiterates-jade-biosciences-stock-rating-on-drug-data-93CH-2716578
Stifel maintained its Buy rating and $40 price target for Jade Biosciences (NASDAQ:JBIO) after the company presented preclinical data for JADE301, a drug for Dermatomyositis. JADE301, an anti-IFN-β monoclonal antibody, is designed to improve upon existing treatments with higher potency and a longer half-life, with a Phase 1 trial expected in Q4 2026. This positive outlook is further supported by recent developments for other Jade Biosciences' drugs, including a price target increase from Wedbush and validation of JADE101 for IgA nephropathy.
Advertisement

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

https://www.globenewswire.com/news-release/2026/09/30/3371748/0/en/jade-biosciences-announces-preclinical-data-characterizing-jade301-a-potentially-best-in-class-half-life-extended-anti-ifn-%CE%B2-monoclonal-antibody-in-development-for-dermatomyositis-.html
Jade Biosciences announced preclinical data for JADE301, an anti-IFN-β monoclonal antibody for dermatomyositis, highlighting its high-affinity binding, greater functional potency, and extended half-life compared to a comparator. The company plans to initiate a Phase 1 healthy volunteer trial in Q4 2026, with interim data expected in H2 2027. JADE301 is designed for infrequent subcutaneous dosing to provide durable improvement for patients.

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

https://finance.yahoo.com/healthcare/articles/jade-biosciences-announces-preclinical-data-110000516.html
Jade Biosciences has announced preclinical data for JADE301, a novel anti-IFN-β monoclonal antibody for dermatomyositis, presented at EADV 2026. The data highlight JADE301's high affinity, potent IFN-β neutralization, extended half-life, and favorable tolerability, suggesting its potential for infrequent subcutaneous dosing. A Phase 1 trial in healthy volunteers is expected to begin in Q4 2026.

Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026

https://www.tradingview.com/news/reuters.com,2026:newsml_TUA7SQT57:0-jade-biosciences-announces-preclinical-data-characterizing-jade301-a-potentially-best-in-class-half-life-extended-anti-ifn-monoclonal-antibody-in-development-for-dermatomyositis-at-eadv-2026/
Jade Biosciences has announced preclinical data for Jade301, a novel half-life-extended anti-IFN-β monoclonal antibody. This drug is being developed for dermatomyositis and is positioned as a potentially best-in-class treatment. The data was presented at EADV 2026.

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

https://sg.finance.yahoo.com/news/jade-biosciences-announces-preclinical-data-110000516.html
Jade Biosciences announced preclinical data for JADE301, a half-life-extended anti-IFN-β monoclonal antibody developed for dermatomyositis, at EADV 2026. The data show JADE301's high-affinity, selective IFN-β binding, greater functional potency than a comparator, and an extended half-life with predictable distribution into muscle in non-human primates. A Phase 1 healthy volunteer trial is expected to begin in Q4 2026, with interim data anticipated in H2 2027.

Jade Biosciences reports preclinical data for dermatomyositis drug

https://www.investing.com/news/company-news/jade-biosciences-reports-preclinical-data-for-dermatomyositis-drug-93CH-4924744
Jade Biosciences announced promising preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data, presented at the 2026 European Academy of Dermatology and Venereology Congress, demonstrated JADE301's strong binding and inhibition of IFN-β signaling, along with a favorable safety profile in non-human primates. The company plans to initiate a Phase 1 trial in healthy volunteers in Q4 2026, with interim data expected in the second half of 2027.
Advertisement

Jade Biosciences at Stifel 2026 Virtual Immunology and Inflammation Forum: Pipeline Push

https://ca.investing.com/news/stock-market-news/jade-biosciences-at-stifel-2026-virtual-immunology-and-inflammation-forum-pipeline-push-93CH-4850244
Jade Biosciences presented its clinical strategy at the Stifel 2026 Virtual Immunology and Inflammation Forum, focusing on three licensed autoimmune programs. The company highlighted encouraging biomarker data for its lead IgAN candidate, JADE101, which aims for deeper and earlier proteinuria reduction with a convenient quarterly dosing schedule. Despite a recent stock drop, management emphasized the company's strong financial position and ongoing progress in its pipeline, including JADE201 for B-cell mediated autoimmune diseases and JADE301 for dermatomyositis, with data and study initiations planned for 2027 and late 2024 respectively.

Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101

https://www.investing.com/news/transcripts/jade-biosciences-at-wells-fargo-conference-pipeline-bets-on-jade-101-93CH-4892444
Jade Biosciences (JBIO) outlined its three-drug strategy for autoimmune diseases at the Wells Fargo 21st Annual Healthcare Conference, focusing on its lead IgA nephropathy candidate, JADE 101. The company highlighted strong early biomarker data for JADE 101, showing a significant reduction in serum IgA, and confirmed a cash runway into Q4 2028 to fund all three programs. Management also discussed its competitive positioning, pipeline expansion with JADE 201 and JADE 301, and its focus on selective APRIL inhibition for better efficacy and safety.

Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48

https://www.moomoo.com/news/post/75786803/clear-street-maintains-jade-biosciences-jbious-with-buy-rating-raises
Clear Street has reiterated its Buy rating for Jade Biosciences (JBIO.US) and increased the target price to $48. This indicates continued confidence in the company's performance and future prospects from the analytical firm.

Jade Biosciences to Participate in Upcoming Conferences

https://www.globenewswire.com/news-release/2026/09/01/3353942/0/en/jade-biosciences-to-participate-in-upcoming-conferences.html
Jade Biosciences announced its participation in four upcoming healthcare and biopharma conferences in September 2026: the Wells Fargo, Citi, H.C. Wainwright, and Stifel forums. Management will host one-on-one investor meetings, and webcasts of the first three fireside chats will be available on the company's website. The company is a clinical-stage biotechnology firm developing therapies for autoimmune diseases.

Jade Biosciences to Participate in Upcoming Conferences

https://uk.finance.yahoo.com/news/jade-biosciences-participate-upcoming-conferences-110000116.html
Jade Biosciences announced its participation in four upcoming healthcare and investment conferences in September 2026. Management will host one-on-one investor meetings, and webcasts of some fireside chats will be available on the company's website. Jade Biosciences is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases.
Advertisement

Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027

https://pluang.com/en/news-feed/jade-biosciences-durasi-adalah-produk-nyata
Jade Biosciences is progressing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), with encouraging Phase 1 results showing a significant reduction in IgA levels and a good safety profile. The company aims for quarterly dosing to improve patient adherence compared to competitors. Key interim results from the Phase 2 JUNIPER trial are anticipated in 2027.

Jade Biosciences Company Profile & Introduction

https://www.moomoo.com/stock/JBIO-US/company?chain_id=Name1K9-3FXPhg.1kulck0&global_content=%7B%22promote_id%22%3A%2213764%22,%22sub_promote_id%22%3A%2280%22,%22f%22%3A%22www.moomoo.com%2Fmy%2Fhans%2Flearn%2Fdetail-6-etf-concerns-that-investors-shouldn-t-overlook-95442-230206065%22%7D
This document is intended to be a company profile and introduction for Jade Biosciences. The content is currently empty, suggesting it will provide foundational information about the company.

Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights

https://es.benzinga.com/quote/JBIO/report
This report provides a financial analysis of Jade Biosciences (JBIO), a clinical-stage biotechnology company. It covers stock performance, future growth potential based on analyst ratings, and past performance metrics like the Sharpe ratio. The company is focused on developing therapies for autoimmune diseases with its flagship candidate, JADE101, currently in Phase 1 clinical trials.

H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55

https://www.moomoo.com/news/post/74581535/hc-wainwright-maintains-jade-biosciences-jbious-with-buy-rating-maintains
H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

https://www.sahmcapital.com/news/content/jade-biosciences-jbio-shares-just-moved-so-what-is-going-on-2026-08-13
Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average analyst target. The company remains unprofitable, with a Price-to-Book ratio of 3.4x, which is considered overvalued compared to industry peers.
Advertisement

Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jbio/jade-biosciences/news/jade-biosciences-jbio-shares-just-moved-so-what-is-going-on
Jade Biosciences (JBIO) recently reported a Q2 2026 net loss of $55.77 million and a basic loss per share of $0.76. Despite strong year-to-date and one-year shareholder returns of 63.91% and 216.64% respectively, the stock has pulled back 3.81% over 90 days and trades at $23.21, significantly below the average analyst target of $50.13. The company's price-to-book ratio of 3.4x is considered overvalued compared to industry peers, reflecting expectations for its drug pipeline rather than current financial performance, as it remains unprofitable with no reported revenue.

Jade Biosciences Is Maintained at Buy by BTIG

https://www.moomoo.com/news/post/74483972/jade-biosciences-is-maintained-at-buy-by-btig?futusource=news_newspage_recommend
BTIG has reiterated its "Buy" rating for Jade Biosciences. This indicates continued confidence from the firm in the company's stock performance.

Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research

https://www.marketbeat.com/instant-alerts/jade-biosciences-nasdaqjbio-given-new-7700-price-target-at-btig-research-2026-08-11/
BTIG Research has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $77.00 from $74.00, reiterating a "buy" rating with a potential upside of 254.35%. Despite this, the company reported a quarterly loss of $0.76 per share, missing consensus estimates, and analysts anticipate a full-year loss of $2.54 per share. Institutional investors have recently adjusted their holdings in JBIO, which is a clinical-stage biotechnology company focused on inflammatory skin diseases.

Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside

https://www.tradingview.com/news/tradingview:2182d363f7c48:0-jade-biosciences-inc-stock-12-month-price-target-raised-to-46-44-implies-111-upside/
Analysts have raised the average 12-month price target for Jade Biosciences, Inc. (JBIO) stock from $45.89 to $46.44, with individual forecasts ranging from $25 to $77 per share. This new target suggests a potential upside of approximately 111% from the Aug. 7 closing price. The consensus rating among 11 analysts remains a "Buy," with no "Holds" or "Sells."

Jade Biosciences Releases Q2 2026 Financial Results

https://news.alphastreet.com/jade-biosciences-releases-q2-2026-financial-results/amp/
Jade Biosciences, Inc. reported a Q2 2026 loss per share of $0.76 and a net loss of $55.8M, reflecting ongoing investment in its biotech development pipeline. The company showed an 11.6% improvement in its per-share loss compared to the prior year. Despite the losses, Wall Street analysts hold a positive outlook, with 8 buy ratings and 1 hold rating.
Advertisement

Wedbush raises Jade Biosciences price target on pipeline progress

https://m.investing.com/news/analyst-ratings/wedbush-raises-jade-biosciences-price-target-on-pipeline-progress-93CH-4849928?ampMode=1
Wedbush has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $47 from $45, maintaining an Outperform rating due to consistent pipeline progress. The firm highlighted positive data for JADE101 in IgAN patients and announced a new program, JADE301, targeting dermatomyositis, expected to enter clinical trials in Q4 2026. This positive outlook follows a significant stock increase and recent financial activities, including a successful public offering and new analyst coverage.

Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth

https://kalkinemedia.com/us/news/announcements/jade-biosciences-announces-q2-2026-financial-results-highlighting-increased-rd-and-asset-growth
Jade Biosciences, Inc. has filed its quarterly report for Q2 2026, revealing a net loss of $96.1 million for the first half of the year. The company's total assets stood at $472.1 million as of June 30, 2026. The financial results highlight increased research and development efforts and overall asset growth.

Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen

https://scanx.trade/stock-market-news/companies/jade-biosciences-q2-results-eps-misses-estimate-losses-widen/47907364
Jade Biosciences reported Q2 EPS of $(0.76), missing the analyst estimate of $(0.64) by 18.75%. This result indicates a widening of operational deficits, with a 11.63% increase in losses compared to the prior year's $(0.86) per share loss. The company's financial performance highlights challenges in cost management or revenue generation, raising investor concerns about near-term profitability.

Jade Biosciences reports $55.8 million Q2 net loss

https://www.quiverquant.com/news/Jade+Biosciences+reports+%2455.8+million+Q2+net+loss
Jade Biosciences (JBIO) reported a Q2 2026 net loss of $55.8 million, an increase from $32.1 million a year prior. Despite the loss, the company holds $461.2 million in cash and expects its runway to extend into Q4 2028. The biotechnology firm provided updates on its clinical trials, including Phase 2 testing for JADE101, a Phase 1 trial for JADE201, and the introduction of JADE301, alongside a recent $172.5 million public offering.

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

https://www.manilatimes.net/2026/08/10/tmt-newswire/globenewswire/jade-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate-update/2401913/amp
Jade Biosciences announced its second quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 in IgA nephropathy and the initiation of a Phase 2 trial. The company also reported progress in its pipeline with JADE201 for rheumatoid arthritis and JADE301 for dermatomyositis, anticipating further clinical trial initiations and data readouts in 2027. Jade Biosciences finished the quarter with $461.2 million in cash, cash equivalents, and investments, projected to fund operations into the fourth quarter of 2028.
Advertisement

Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3

https://www.tradingview.com/news/tradingview:472be96eb93e4:0-jade-biosciences-reports-q2-net-loss-55-8m-cash-461-2m-advances-jade101-to-phase-2-3/
Jade Biosciences reported a Q2 2026 net loss of $55.8 million, with $461.2 million in cash, cash equivalents, and investments, providing a financial runway into Q4 2028. The company highlighted positive interim Phase 1 results for JADE101, which is advancing to Phase 2/3 trials for IgA nephropathy, and progressed other clinical programs including JADE201 and JADE301. R&D expenses increased to $50.1 million, reflecting heightened clinical and CMC activities.

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

https://www.globenewswire.com/news-release/2026/08/10/3341688/0/en/jade-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Jade Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 for IgA nephropathy, with a Phase 2 trial underway and a Phase 3 trial expected to begin in early 2027. The company also initiated dosing for JADE201 in rheumatoid arthritis and unveiled JADE301 for dermatomyositis, with a Phase 1 trial planned for Q4 2026. Jade Biosciences reported $461 million in cash, cash equivalents, and investments as of June 30, 2026, projected to fund operations into Q4 2028.

Jade Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview

https://www.tradingview.com/news/reuters.com,2026:newsml_L8N4441RP:0-jade-biosciences-inc-expected-to-post-a-loss-of-64-cents-a-share-earnings-preview/
Jade Biosciences Inc (JBIO) is projected to report a loss of 64 cents per share. This information comes from a Reuters earnings preview available on TradingView, with further details behind a paywall requiring unlimited access to news sources.

Jade Biosciences (Nasdaq:JBIO) - Stock Analysis

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jbio/jade-biosciences
Jade Biosciences (Nasdaq:JBIO) is a biotechnology company developing therapies for autoimmune diseases, primarily focusing on JADE101 for IgA nephropathy. The company has a market cap of US$1.3 billion but is currently unprofitable and its earnings are forecasted to decline. Recent news highlights include positive Phase 1 results for JADE101, its advancement into Phase 2, a $150 million equity offering, and new executive appointments.

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

https://finance.yahoo.com/healthcare/articles/jade-biosciences-inc-jbio-stock-132113346.html
Jade Biosciences, Inc. (JBIO) is highlighted as a promising biotech opportunity in the $20 billion IgA nephropathy market, with UBS initiating coverage with a Buy rating and a $45 price target for its lead program, JADE101. The company announced positive interim Phase 1 study findings for JADE101, showing significant IgA level reductions and a favorable safety profile, with plans to advance to Phase 2 and Phase 3 trials. Despite this potential, the article suggests that certain AI stocks may offer greater upside and less risk.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement